Ravin Talati, MD
Family Medicine · Demorest, GANPI 1598920357
Payments from drug & device makers
Across 281 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$705
- Amgen$540
- Astellas Pharma US Inc$440
- GSK$430
- AbbVie$372
- AstraZeneca$250
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,12995%
- Education$2325%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 50 | $705 |
| Amgen | 35 | $540 |
| Astellas Pharma US Inc | 24 | $440 |
| GSK | 29 | $430 |
| AbbVie(2 entities) | 34 | $372 |
| AstraZeneca | 16 | $250 |
| Otsuka America Pharmaceutical, Inc. | 10 | $185 |
| Lilly USA, LLC | 11 | $151 |
| Sanofi-aventis U.S. LLC | 9 | $141 |
| Corcept Therapeutics | 6 | $136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $136 |
| Novartis | 7 | $114 |
| Pfizer | 6 | $105 |
| Sumitomo Pharma America, Inc. | 6 | $98 |
| Sunovion Pharmaceuticals Inc. | 5 | $96 |
| Boehringer Ingelheim | 4 | $92 |
| Amarin Pharma, Inc. | 3 | $60 |
| Daiichi Sankyo Inc. | 4 | $58 |
| Exact Sciences | 3 | $48 |
| Merck | 3 | $40 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Bayer | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
How this compares
$4,361 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 152 | $222,151 |
| MounjaroTirzepatide | 134 | $165,267 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 148 | $116,645 |
| EliquisApixaban | 114 | $81,896 |
| LinzessLinaclotide | 79 | $69,329 |
| XareltoRivaroxaban | 60 | $56,871 |
| Repatha SureclickEvolocumab | 84 | $53,621 |
| Metformin Er GastricMetformin Hcl | 21 | $50,526 |
| Nurtec OdtRimegepant Sulfate | 34 | $49,117 |
| FarxigaDapagliflozin Propanediol | 65 | $45,629 |
| RexultiBrexpiprazole | 20 | $39,682 |
| MyrbetriqMirabegron | 48 | $37,279 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $33,539 |
| RybelsusSemaglutide | 12 | $33,051 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $31,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $705 | $255,202164 claims |
| Lilly USA, LLCMounjaro, Trulicity | $151 | $181,690151 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $430 | $141,967220 claims |
| PfizerEliquis, Nurtec Odt | $105 | $131,012148 claims |
| AbbVieLinzess, Viberzi | $372 | $84,97790 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $250 | $60,68894 claims |
| Boehringer IngelheimGlyxambi, Jardiance | $92 | $59,33352 claims |
| Johnson & JohnsonXarelto | $16 | $56,87160 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $185 | $39,68220 claims |
| Astellas Pharma US IncMyrbetriq | $440 | $37,27948 claims |
| MerckJanuvia | $40 | $25,10829 claims |
| NovartisEntresto | $114 | $17,08819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Demorest
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.